Skip to main content
Fig. 13 | BMC Cancer

Fig. 13

From: Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Fig. 13

Forest Plot of Progression-free Survival Treatment Comparison. Estimates derived only from indirect comparisons shown in black box. Included references: Study 301 (Kaufman 2015; Twelves 2016), EMBRACE (Twelves 2015; Cardoso 2011; Cortes 2011), CA163–046 (Hortobagyi 2010; Rugo 2018), Sparano 2010, Pallis 2012, Zhang 2017. Abbreviations: CAP = capecitabine; CrI = credible interval; ERI = eribulin; GEM = gemcitabine; IXA = ixabepilone; TPC = treatment by physician’s choice; UTI = utidelone; VIN = vinorelbine

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us